A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status

• Status: Completed
• Trial end date: 2019-03-31
• Target enrollment: 0
• Participant gender: All

Summary

A clinical trial to investigate the appropriate dose of isoniazid according to NAT2 polymorphism status in Korean subjects

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborator: Ministry of Health & Welfare, Korea
• Treatments: Isoniazid

Criteria

Inclusion Criteria:

• Agreement with written informed consent

• Adult healthy male or female subject age 20 to 45

Exclusion Criteria:

• Clinically significant, active gastrointestinal system, cardiovascular system, pulmonary system, renal system, endocrine system, blood system, digestive system, central nervous system, mental disease or malignancy

• Medication with any drug which may affect the pharmacokinetics of isoniazid within 14 days

• Previously donate whole blood within 30 days or Previously participated in other trial within 60 days

• Subject with known for hypersensitivity reactions to isoniazid

• Subject who can not perform contraception during study periods

• Female woman who are pregnant or are breast feeding

• An impossible one who participates in clinical trial by investigator's decision including laboratory test result